Page last updated: 2024-12-07

3-formylrifamycin sv

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID122869
MeSH IDM0116953

Synonyms (8)

Synonym
13292-22-3
3-formylrifamycin sv
AKOS030228252
3-formylrifamycinsv
[(7s,11s,12r,13s,14r,15r,16r,17s,18s)-26-formyl-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
PD044249
PD040256
DTXSID201043051

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of the active, orally administered rifampicin decreased from 93% after the first single oral dose to 68% after 3 weeks of oral and intravenous rifampicin therapy."( Pharmacokinetics of oral and intravenous rifampicin during chronic administration.
Eichelbaum, M; Jensen, JC; Loos, U; Mikus, G; Musch, E; Schwabe, HK, 1985
)
0.27
"Rifampicin (RIF) hydrolyzes in acidic medium to form insoluble and poorly absorbed 3-Formyl rifamycin SV (3-FRSV)."( Stability of rifampicin in dissolution medium in presence of isoniazid.
Kotecha, JS; Rathod, IS; Savale, SS; Shah, PB; Shah, SA; Shishoo, CJ, 1999
)
0.3

Dosage Studied

ExcerptRelevanceReference
" Therapeutic activities of R-76-1 versus RMP and DL 473 versus RMP were compared, respectively, in the experimental infection of mice with Mycobacterium lepraemurium by different treatment schedules (immediate and delayed) and dosage regimens."( Antimycobacterial activities of two newer ansamycins, R-76-1 and DL 473.
Chen, JK; Hou, YH; Ji, BH; Lu, XZ; Ni, GX; Tang, QK; Wang, SY; Zhou, DH, 1986
)
0.27
" Thus, lower concentration of RIF may be available for absorption leading to poor bioavailability of RIF from combination dosage forms (RIF+INH) as compared to formulations containing only RIF."( Stability of rifampicin in dissolution medium in presence of isoniazid.
Kotecha, JS; Rathod, IS; Savale, SS; Shah, PB; Shah, SA; Shishoo, CJ, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (42.86)18.7374
1990's1 (14.29)18.2507
2000's0 (0.00)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.87 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (12.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]